MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.71 -4.47

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.69

Max

1.78

Põhinäitajad
By Trading Economics
Sissetulek	-2.8M -16M
Müük	-8.7M 5.5M
Kasumimarginaal	-282.723
Töötajad	81
EBITDA	-4.2M -15M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+117.61% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	22M 674M
Eelmine avamishind	6.18
Eelmine sulgemishind	1.71

Uudiste sentiment

By Acuity

11%

89%

17 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB: Higher Energy Prices to Raise Production, Consumer Costs

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

9. apr 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9. apr 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9. apr 2026, 23:14 UTC

Market Talk

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9. apr 2026, 23:14 UTC

Market Talk

Global Equities Roundup: Market Talk

9. apr 2026, 23:07 UTC

Market Talk

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9. apr 2026, 22:54 UTC

Market Talk

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9. apr 2026, 22:31 UTC

Uudisväärsed sündmused

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9. apr 2026, 22:31 UTC

Uudisväärsed sündmused

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9. apr 2026, 20:57 UTC

Uudisväärsed sündmused

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9. apr 2026, 20:55 UTC

Tulu

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9. apr 2026, 20:55 UTC

Tulu

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9. apr 2026, 20:55 UTC

Tulu

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9. apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

9. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. apr 2026, 20:40 UTC

Omandamised, ülevõtmised, äriostud

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9. apr 2026, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9. apr 2026, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Rowan Digital Infrastructure Announces Strategic Recapitalization

9. apr 2026, 20:25 UTC

Omandamised, ülevõtmised, äriostud

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9. apr 2026, 19:30 UTC

Uudisväärsed sündmused

How Digital Currencies Have Helped Iran -- WSJ

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

117.61% tõus

12 kuu keskmine prognoos

Keskmine 3.83 USD 117.61%

Kõrge 6 USD

Madal 1 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

17 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.